Enlivex Therapeutics (ENLV) Q2 2025 earnings summary

Executive summary

• Positive three-month topline data from a Phase I/II trial of Allocetra in moderate-to-severe knee osteoarthritis showed significant improvements in pain and function, with a favorable safety profile.

• Focus shifted to inflammatory and autoimmune indications, with sepsis and oncology programs now candidates for external collaboration or out-licensing.

• Workforce reduced by 50% over the past year to align with reprioritized clinical focus.

Financial highlights

• Net loss for the six months ended June 30, 2025 was $5.3M, down 26% year-over-year; Q2 net loss was $1.87M, down 40% year-over-year.

• Operating loss for the six months was $6.6M, a 7% decrease from the prior year; Q2 operating loss was $3.08M, up 3% year-over-year.

• Finance income for the six months was $1.29M, up from a $99K loss in the prior year, driven by interest income and favorable FX movements.

• Cash and cash equivalents plus short-term deposits totaled $19.5M as of June 30, 2025.

• Net cash used in operations for the six months was $5.82M, down from $6.31M in the prior year.

Outlook and guidance

• Existing resources expected to fund operations through the end of 2026, including planned clinical milestones.

• Additional funding will be required for further development, regulatory approval, and commercialization.